Corey Walker rejoins Avantor as President of Laboratory Solutions, bringing extensive experience in life sciences and advanced technologies.
 |
| Avantor Appoints Mr. Corey Walker as its President |
Avantor, a leading global provider of mission-critical products and services to the life sciences and advanced technologies industries, announced today that Corey Walker has rejoined the company as President of Avantor's Laboratory Solutions business. Walker will report directly to CEO Michael Stubblefield.
"Corey's deep knowledge of our end markets and industry, coupled with his familiarity with our organization and customers, makes him the ideal leader for our Laboratory Solutions business," said Michael Stubblefield. "We are very excited to welcome Corey back to Avantor to advance our business transformation and accelerate our growth strategy."
Walker brings a wealth of experience and expertise to his new role. Most recently, he served as Chief Executive Officer of ILC Dover, a global supplier to the biopharma and medical device markets. From 2016 to 2020, Walker was an Executive Vice President at Avantor, where he led the Americas region as well as the global Biomaterials and Electronic Materials businesses. He holds a bachelor's degree in marketing and business management from Brigham Young University and an MBA from Harvard Business School.
"Avantor has established an enviable market position, portfolio, and value proposition," said Corey Walker. "I have always had great respect for Michael and the company, and I look forward to partnering with the team to enhance the customer experience, accelerate our transformation, and drive growth."
Walker succeeds Randy Stone, who served as Executive Vice President of Laboratory Solutions. "We appreciate Randy's contributions to Avantor, including leading a best-in-class Laboratory Solutions segment team and advancing our business transformation, and we wish him continued success," added Stubblefield.
Avantor's new operating model, which includes two global operating segments – Laboratory Solutions and Bioscience Production – became effective in January 2024. The company is reaffirming its fiscal year 2024 guidance, as last reaffirmed during its first quarter earnings call.